HOWL Werewolf Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 31, 2026
$0.93
· % 处于52周区间
· 高于低点
· 至高点
$0.2752周低点
$2.1552周高点
市值 (MRQ)
$45M
P/E
-0.7
EPS
$-1.33
HOWL 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$0.93
市值 (MRQ)
$45M
P/E
-0.7
EPS
$-1.33
ROE
-183.6%
负债/权益 (MRQ)
0.0
52周区间
$0–$2
HOWL 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
10年表现 收入、净利润、利润率和每股收益趋势
EPS$-1.332020-12-31 → 2025-12-31
自由现金流$-60M2021-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | HOWL | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -0.75年均值 ≈-1.5 | ≈-1.5 | · | · | |
| 市净率 (MRQ) | 2.85年均值 ≈1.2 | ≈1.2 | 0.8 | 估值过高 | |
| EV / EBITDA (企业价值 / EBITDA) | -0.35年均值 ≈-0.0 | ≈-0.0 | · | · | |
| Price / FCF (股价/自由现金流) | -0.75年均值 ≈-3.0 | ≈-3.0 | · | · | |
| Price / Cash Flow (市现率) | -0.75年均值 ≈-3.1 | ≈-3.1 | · | · | |
| EV / FCF (市值/自由现金流) | -0.35年均值 ≈0.0 | ≈0.0 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 1.85年均值 ≈1.2 | ≈1.2 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | HOWL | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -62.0%5年均值 ≈-39.8% | ≈-39.8% | -69.2% | 持平 | |
| ROE | -183.6%5年均值 ≈-75.4% | ≈-75.4% | -94.1% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | HOWL | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.05年均值 ≈0.4 | ≈0.4 | · | · | |
| 流动比率 (MRQ) | 2.95年均值 ≈7.1 | ≈7.1 | 4.2 | 低流动性 | |
| Quick Ratio (速动比率) | 1.65年均值 ≈6.9 | ≈6.9 | 2.2 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
29.3%
下次报告
十一月 02, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | $0.08 | $-0.27 | 130.2% | |
| 2026年3月31日 | $-0.28 | $-0.29 | 3.7% | |
| 2025年12月31日 | $-0.17 | $-0.35 | 51.7% | |
| 2025年9月30日 | $-0.36 | $-0.40 | 9.5% | |
| 2025年6月30日 | $-0.40 | $-0.49 | 17.6% | |
| 2025年3月31日 | $-0.40 | $-0.40 | 0.47% | |
| 2024年12月31日 | $-0.46 | $-0.43 | -7.8% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $45M | $56M | $42M | $54M | $35M | $17M | |
| SG&A Expense | $16M | $19M | $19M | $19M | $15M | $6M | |
| Operating Expenses | $61M | $75M | $60M | $72M | $50M | $22M | |
| Operating Income | $-61M | $-74M | $-41M | $-56M | $-50M | $-22M | |
| Interest Expense | · | · | $3M | $0 | · | · | |
| Interest Income | $3M | $7M | $7M | $2M | · | · | |
| Other Non-op | $2M | $2M | $-1M | $338.0K | $104.0K | $7M | |
| Income Tax | $0 | · | · | · | · | · | |
| Net Income | $-61M | $-71M | $-37M | $-54M | $-50M | $-15M | |
| EPS (Basic) | $-1.32 | $-1.63 | $-1.05 | $-1.86 | $-10.94 | $-28.08 | |
| EPS (Diluted) | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 | $-28.08 | |
| Shares (Basic) | 46,018,888 | 43,332,088 | 35,646,572 | 28,863,935 | 18,455,000 | 1,005,000 | |
| Shares (Diluted) | 46,810,252 | 43,859,664 | 35,646,572 | 28,863,935 | 18,455,000 | 1,005,000 | |
| EBITDA | $-61M | $-74M | $-41M | $-56M | $-50M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $57M | $111M | $134M | $129M | $158M | $93M | |
| Prepaid Expense | $2M | $2M | $3M | $4M | $4M | $344.0K | |
| Current Assets | $59M | $113M | $138M | $140M | $161M | $93M | |
| PP&E (Net) | $5M | $6M | $8M | $9M | $3M | $651.0K | |
| PP&E (Gross) | $11M | $11M | $11M | $10M | $3M | $826.0K | |
| Accum. Depreciation | · | · | · | · | $391.0K | · | |
| Other Non-current Assets | $5.0K | $320.0K | $594.0K | $1M | $649.0K | $0 | |
| Total Assets | $69M | $127M | $175M | $160M | $179M | $96M | |
| Accounts Payable | $754.0K | $3M | $1M | $1M | $2M | $1M | |
| Accrued Liabilities | $5M | $11M | $9M | $14M | $9M | $4M | |
| Short-term Debt | $28M | $0 | $7M | $0 | · | · | |
| Current Liabilities | $36M | $15M | $19M | $24M | $12M | $5M | |
| Capital Leases | $8M | $9M | $11M | $13M | $15M | $2M | |
| Other Non-current Liabilities | · | · | $0 | $191.0K | $0 | $31.0K | |
| Total Liabilities | $45M | $54M | $63M | $38M | $26M | $7M | |
| Long-term Debt | $32M | $32M | $40M | · | · | · | |
| Total Debt | $28M | $0 | $7M | · | · | · | |
| Common Stock | $5.0K | $5.0K | $4.0K | $3.0K | $2.0K | $2.0K | |
| Paid-in Capital | $500M | $488M | $455M | $429M | $406M | $0 | |
| Retained Earnings | $-475M | $-415M | $-344M | $-307M | $-253M | $-52M | |
| Stockholders' Equity | $25M | $73M | $111M | $122M | $153M | $-52M | |
| Liabilities + Equity | $69M | $127M | $175M | $160M | $179M | $96M | |
| Shares Outstanding | 48,596,817 | 44,827,159 | 39,107,048 | 31,515,074 | 27,313,000 | 1,184,000 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $9M | $8M | $7M | $4M | $632.0K | |
| Deferred Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating Cash Flow | $-60M | $-56M | $-33M | $-41M | $-43M | $-19M | |
| CapEx | $0 | $254.0K | $769.0K | $4M | $498.0K | $560.0K | |
| Investing Cash Flow | $0 | $-254.0K | $-769.0K | $-4M | $-498.0K | $-560.0K | |
| Stock Issued | $6M | $24M | $18M | $16M | $0 | · | |
| Net Stock Activity | $6M | $24M | $18M | $16M | · | · | |
| Financing Cash Flow | $6M | $13M | $58M | $16M | $109M | $94M | |
| Net Change in Cash | $-54M | $-43M | $25M | $-28M | $66M | $75M | |
| Free Cash Flow | $-60M | $-56M | $-33M | $-44M | $-43M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| ROA | -62.0% | -46.7% | -22.3% | -31.7% | -36.3% | · | |
| ROE | -183.6% | -86.6% | -33.4% | -42.5% | -31.0% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 7.4 | 7.1 | 5.8 | 13.6 | · | |
| Quick Ratio | 1.6 | 7.3 | 6.9 | 5.4 | 13.3 | · | |
| Debt / Equity | 1.1 | 0.0 | 0.1 | · | · | · | |
| Interest Coverage | · | · | -12.9 | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.51 | $1.64 | $2.85 | $3.89 | $5.59 | · | |
| Cash Flow / Share | $-1.29 | $-1.28 | $-0.91 | $-1.41 | $-2.32 | · | |
| Cash / Share | $1.17 | $2.48 | $3.44 | $4.11 | $5.77 | · | |
| EPS (TTM) | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-61M | $-71M | $-37M | $-54M | $-50M | · | |
| Market Cap | $31M | $66M | $151M | $64M | $325M | · | |
| Enterprise Value | $2M | $-45M | $23M | · | · | · | |
| P/E | -0.5 | -0.9 | -3.7 | -1.1 | -1.1 | · | |
| P/B | 1.2 | 0.9 | 1.4 | 0.5 | 2.1 | · | |
| P / Tangible Book | 1.2 | 0.9 | 1.4 | 0.5 | 2.1 | · | |
| P / Cash Flow | -0.5 | -1.2 | -4.6 | -1.6 | -7.6 | · | |
| P / FCF | -0.5 | -1.2 | -4.5 | -1.5 | -7.5 | · | |
| EV / EBITDA | -0.0 | 0.6 | -0.6 | · | · | · | |
| EV / FCF | -0.0 | 0.8 | -0.7 | · | · | · | |
| Earnings Yield | -209.8% | -110.1% | -27.2% | -90.7% | -91.9% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $6M | $8M | $7M | $12M | $13M | $13M | $16M | $13M | $15M | $13M | $10M | $11M | $10M | $12M | $16M | $13M | |
| SG&A Expense | $8M | $5M | $2M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $4M | |
| Operating Expenses | $14M | $13M | $9M | $16M | $18M | $18M | $20M | $17M | $20M | $18M | $14M | $15M | $14M | $17M | $20M | $18M | |
| Operating Income | $7M | $-13M | $-9M | $-16M | $-18M | $-18M | $-20M | $-17M | $-19M | $-17M | $-13M | $-9M | $-6M | $-12M | $-13M | $-13M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | · | · | $172.0K | · | · | |
| Interest Income | $277.0K | $433.0K | $564.0K | $697.0K | $850.0K | $997.0K | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | · | |
| Other Non-op | $64.0K | $674.0K | $2M | $0 | $11.0K | $168.0K | $-94.0K | $97.0K | $2M | $-1.0K | $-6.0K | $-5.0K | $-25.0K | $-1M | $70.0K | $3.0K | |
| Net Income | $4M | $-14M | $-8M | $-16M | $-18M | $-18M | $-20M | $-17M | $-17M | $-16M | $-12M | $-8M | $-5M | $-12M | $-12M | $-12M | |
| EPS (Basic) | $0.08 | $-0.28 | $-0.16 | $-0.36 | $-0.40 | $-0.40 | $-0.46 | $-0.38 | $-0.40 | $-0.39 | $-0.34 | $-0.23 | $-0.14 | $-0.34 | $-0.37 | $-0.40 | |
| EPS (Diluted) | $0.08 | $-0.28 | $-0.17 | $-0.36 | $-0.40 | $-0.40 | $-0.43 | $-0.38 | $-0.43 | $-0.39 | $-0.34 | $-0.23 | $-0.14 | $-0.34 | $-0.37 | $-0.40 | |
| Shares (Basic) | 48,597,534 | 48,596,817 | · | 45,804,042 | 44,981,746 | 44,827,159 | · | 43,704,836 | 43,521,406 | 41,607,279 | · | 35,653,924 | 35,557,701 | 34,784,682 | · | 29,764,000 | |
| Shares (Diluted) | 48,597,534 | 49,388,181 | · | 45,804,042 | 44,981,746 | 44,827,159 | · | 43,704,836 | 44,043,184 | 41,607,279 | · | 35,653,924 | 35,557,701 | 34,784,682 | · | 29,764,000 | |
| EBITDA | $7M | $-13M | · | $-16M | $-18M | $-18M | · | $-17M | $-19M | $-17M | · | $-9M | $-6M | $-12M | · | $-13M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22M | $46M | $57M | $66M | $78M | $92M | $111M | $123M | $135M | $139M | $134M | $130M | $137M | $148M | $129M | $140M | |
| Prepaid Expense | $905.0K | $2M | $2M | $2M | $3M | $2M | $2M | $3M | $3M | $2M | $3M | $3M | $3M | $2M | $4M | $7M | |
| Current Assets | $23M | $49M | $59M | $68M | $80M | $94M | $113M | $126M | $139M | $142M | $138M | $139M | $147M | $157M | $140M | $152M | |
| PP&E (Net) | $1M | $4M | $5M | $5M | $5M | $6M | $6M | $7M | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $9M | |
| PP&E (Gross) | · | · | $11M | · | · | · | $11M | · | · | · | $11M | · | · | · | $10M | $10M | |
| Accum. Depreciation | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $992.0K | |
| Other Non-current Assets | $0 | $0 | $5.0K | $46.0K | $122.0K | $179.0K | $320.0K | $42.0K | $265.0K | $248.0K | $594.0K | $516.0K | $652.0K | $670.0K | $1M | $2M | |
| Total Assets | $24M | $58M | $69M | $80M | $93M | $107M | $127M | $140M | $154M | $178M | $175M | $176M | $185M | $195M | $160M | $172M | |
| Accounts Payable | $2M | $4M | $754.0K | $1M | $3M | $986.0K | $3M | $1M | $1M | $2M | $1M | $1M | $1M | $2M | $1M | $1M | |
| Accrued Liabilities | $6M | $5M | $5M | $9M | $9M | $9M | $11M | $10M | $9M | $6M | $9M | $8M | $10M | $13M | $14M | $14M | |
| Short-term Debt | $0 | $29M | $28M | $6M | $2M | · | $0 | $0 | $0 | $12M | $7M | $2M | · | · | $0 | · | |
| Current Liabilities | $8M | $39M | $36M | $18M | $15M | $12M | $15M | $12M | $11M | $21M | $19M | $14M | $15M | $22M | $24M | $28M | |
| Capital Leases | $0 | $7M | $8M | $8M | $9M | $9M | $9M | $10M | $10M | $11M | $11M | $11M | $12M | $12M | $13M | $13M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $191.0K | $191.0K | |
| Total Liabilities | $8M | $46M | $45M | $50M | $51M | $50M | $54M | $51M | $50M | $60M | $63M | $64M | $67M | $74M | $38M | $41M | |
| Long-term Debt | · | $32M | $32M | $32M | $32M | $32M | · | $32M | $32M | $40M | · | · | · | · | · | · | |
| Total Debt | $0 | $29M | · | $6M | $2M | · | · | $0 | $0 | $12M | · | $2M | · | · | · | · | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $3.0K | $3.0K | $3.0K | $3.0K | $3.0K | |
| Paid-in Capital | $502M | $501M | $500M | $497M | $492M | $490M | $488M | $484M | $482M | $478M | $455M | $445M | $442M | $440M | $429M | $426M | |
| Retained Earnings | $-485M | $-489M | $-475M | $-467M | $-451M | $-433M | $-415M | $-394M | $-378M | $-360M | $-344M | $-332M | $-324M | $-319M | $-307M | $-295M | |
| Stockholders' Equity | $16M | $12M | $25M | $30M | $41M | $57M | $73M | $89M | $104M | $118M | $111M | $112M | $119M | $121M | $122M | $131M | |
| Liabilities + Equity | $24M | $58M | $69M | $80M | $93M | $107M | $127M | $140M | $154M | $178M | $175M | $176M | $185M | $195M | $160M | $172M | |
| Shares Outstanding | 48,599,066 | 48,596,817 | 48,596,817 | 47,273,685 | 45,335,265 | 44,827,159 | 44,827,159 | 43,721,772 | 43,702,147 | 43,282,371 | 39,107,048 | 35,658,000 | 35,642,000 | 35,301,000 | 31,433,731 | 30,611,000 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $419.0K | $929.0K | $1M | $1M | $2M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $7M | $-11M | $-11M | $-15M | $-15M | $-19M | $-14M | $-12M | $-14M | $-15M | $-5M | $-7M | $-11M | $-10M | $-12M | $-14M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $123.0K | $3.0K | $17.0K | $111.0K | $198.0K | $221.0K | $182.0K | $168.0K | $518.0K | $2M | |
| Investing Cash Flow | · | · | $0 | $0 | $0 | $0 | $-123.0K | $-3.0K | $-17.0K | $-111.0K | $-198.0K | $-221.0K | $-182.0K | $-168.0K | $-518.0K | $-2M | |
| Stock Issued | · | · | $2M | $3M | $347.0K | $0 | $2M | $-29.0K | $877.0K | $20M | $9M | $-84.0K | $552.0K | $9M | $979.0K | $11M | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $20M | · | · | · | $9M | · | · | |
| Financing Cash Flow | · | · | $2M | $3M | $388.0K | $0 | $3M | $-6.0K | $-10M | $20M | $9M | $41.0K | $692.0K | $49M | $1M | $11M | |
| Net Change in Cash | $-25M | $-11M | $-9M | $-12M | $-15M | $-19M | $-12M | $-12M | $-24M | $5M | $4M | $-7M | $-10M | $39M | $-11M | $-5M | |
| Free Cash Flow | · | · | · | · | · | $-19M | · | · | · | $-15M | · | · | · | $-10M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | 6.3% | -16.4% | · | -14.9% | -14.6% | -12.7% | · | -10.5% | -10.2% | -8.7% | · | -4.8% | -2.8% | -6.7% | · | -6.8% | |
| ROE | 12.7% | -38.9% | · | -27.5% | -24.7% | -20.7% | · | -16.5% | -15.5% | -13.6% | · | -6.8% | -4.1% | -9.2% | · | -8.0% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | 1.3 | · | 3.9 | 5.3 | 8.1 | · | 10.1 | 12.1 | 6.7 | · | 9.6 | 9.8 | 7.2 | · | 5.5 | |
| Quick Ratio | 2.8 | 1.2 | · | 3.7 | 5.1 | 7.9 | · | 9.9 | 11.8 | 6.6 | · | 9.0 | 9.2 | 6.8 | · | 5.1 | |
| Debt / Equity | 0.0 | 2.4 | · | 0.2 | 0.1 | · | · | 0.0 | 0.0 | 0.1 | · | 0.0 | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -17.1 | · | · | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.34 | $0.25 | · | $0.63 | $0.91 | $1.28 | · | $2.04 | $2.38 | $2.72 | · | $3.15 | $3.33 | $3.43 | · | $4.28 | |
| Cash Flow / Share | · | $-0.21 | · | · | · | $-0.42 | · | · | · | $-0.37 | · | · | · | $-0.28 | · | · | |
| Cash / Share | $0.45 | $0.96 | · | $1.39 | $1.71 | $2.05 | · | $2.81 | $3.10 | $3.22 | · | $3.65 | $3.86 | $4.19 | · | $4.59 | |
| EPS (TTM) | $-0.73 | $-1.21 | · | $-1.59 | $-1.61 | $-1.64 | · | $-1.54 | $-1.39 | $-1.10 | · | $-1.08 | $-1.25 | $-1.64 | · | $75.26 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-35M | $-56M | · | $-73M | $-73M | $-72M | · | $-62M | $-54M | $-42M | · | $-37M | $-41M | $-50M | · | $-60M | |
| Market Cap | $17M | $40M | · | $93M | $49M | $44M | · | $93M | $107M | $280M | · | $76M | $109M | $92M | · | $138M | |
| Enterprise Value | $-4M | $23M | · | $33M | $-26M | · | · | $-30M | $-29M | $153M | · | $-52M | · | · | · | · | |
| P/E | -0.5 | -0.7 | · | -1.2 | -0.7 | -0.6 | · | -1.4 | -1.8 | -5.9 | · | -2.0 | -2.4 | -1.6 | · | 0.1 | |
| P/B | 1.1 | 3.3 | · | 3.1 | 1.2 | 0.8 | · | 1.0 | 1.0 | 2.4 | · | 0.7 | 0.9 | 0.8 | · | 1.1 | |
| P / Tangible Book | 1.1 | 3.3 | · | 3.1 | 1.2 | 0.8 | · | 1.0 | 1.0 | 2.4 | · | 0.7 | 0.9 | 0.8 | · | 1.1 | |
| P / Cash Flow | · | -3.8 | · | · | · | -2.3 | · | · | · | -18.3 | · | · | · | -9.3 | · | · | |
| Earnings Yield | -202.8% | -145.3% | · | -80.7% | -147.7% | -168.7% | · | -72.6% | -57.0% | -17.0% | · | -50.5% | -41.0% | -63.1% | · | 1668.7% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 净收入 | $-61M | $-71M | $-37M | $-54M | $-50M |
| 稀释后每股收益 (EPS) | $-1.33 | $-1.63 | $-1.05 | $-1.86 | $-10.94 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 1.1 | 0.0 | 0.1 | · | · |
| 流动比率 | 1.6 | 7.4 | 7.1 | 5.8 | 13.6 |
| 速动比率 | 1.6 | 7.3 | 6.9 | 5.4 | 13.3 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-60M | $-56M | $-33M | $-44M | $-43M |
机构持有人 (13F) 53 家申报者 · $13.4M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
53
持有价值
$13.4M
新仓位
11
已退出持仓
11
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 11 (+1 与上一季度对比) | 11 (0 与上一季度对比) | 9 (0 与上一季度对比) | 9 (-3 与上一季度对比) | -3.0M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | $8490424 | 4309860 | 63.19% | 股份 |
| VANGUARD GROUP INC | $892702 | 1408047 | 6.64% | 股份 |
| RA CAPITAL MANAGEMENT, L.P. | $859349 | 2387744 | 6.40% | 股份 |
| Balyasny Asset Management L.P. | $644253 | 1790089 | 4.79% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $438471 | 1217976 | 3.26% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $242800 | 674632 | 1.81% | 股份 |
| Lynx1 Capital Management LP | $236737 | 657786 | 1.76% | 股份 |
| SPHERA FUNDS MANAGEMENT LTD. | $225589 | 626810 | 1.68% | 股份 |
| DC Funds, LP | $212018 | 589102 | 1.58% | 股份 |
| Verdad Advisers, LP | $125500 | 348709 | 0.93% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $120895 | 335815 | 0.90% | 股份 |
| BANK OF AMERICA CORP /DE/ | $111829 | 311502 | 0.83% | 股份 |
| XTX Topco Ltd | $97705 | 271478 | 0.73% | 股份 |
| Cubist Systematic Strategies, LLC | $92020 | 46711 | 0.68% | 股份 |
| JANE STREET GROUP, LLC | $90637 | 251837 | 0.67% | 股份 |
| UBS Group AG | $77702 | 215838 | 0.58% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $56781 | 157726 | 0.42% | 股份 |
| STATE STREET CORP | $42889 | 119168 | 0.32% | 股份 |
| Squarepoint Ops LLC | $37157 | 103242 | 0.28% | 股份 |
| BlackRock, Inc. | $36556 | 101573 | 0.27% | 股份 |
| Rangeley Capital, LLC | $35990 | 100000 | 0.27% | 股份 |
| NORTHERN TRUST CORP | $31258 | 86851 | 0.23% | 股份 |
| Alyeska Investment Group, L.P. | $31151 | 86554 | 0.23% | 股份 |
| MPM BIOIMPACT LLC | $28851 | 80142 | 0.21% | 股份 |
| CITADEL ADVISORS LLC | $26993 | 75000 | 0.20% | 买入期权 |
| Point72 Asia (Singapore) Pte. Ltd. | $25642 | 13016 | 0.19% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $22334 | 62055 | 0.17% | 股份 |
| H D Vest Advisory Services | $11118 | 10200 | 0.08% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $9825 | 27300 | 0.07% | 股份 |
| StoneX Group Inc. | $9000 | 20000 | 0.07% | 股份 |
| GOLDMAN SACHS GROUP INC | $7206 | 20023 | 0.05% | 股份 |
| MORGAN STANLEY | $6877 | 19108 | 0.05% | 股份 |
| TWO SIGMA ADVISERS, LP | $6525 | 10300 | 0.05% | 股份 |
| CITADEL ADVISORS LLC | $5578 | 15500 | 0.04% | 卖出期权 |
| CERTUITY, LLC | $5399 | 15000 | 0.04% | 股份 |
| HBK Sorce Advisory LLC | $5317 | 13227 | 0.04% | 股份 |
| BARCLAYS PLC | $4763 | 13235 | 0.04% | 股份 |
| Larson Financial Group LLC | $4697 | 13052 | 0.03% | 股份 |
| LPL Financial LLC | $4244 | 11791 | 0.03% | 股份 |
| Ranch Capital Advisors Inc. | $3959 | 11000 | 0.03% | 股份 |
| Marest Capital, LLC | $3912 | 10870 | 0.03% | 股份 |
| Cetera Investment Advisers | $3671 | 10200 | 0.03% | 股份 |
| Tower Research Capital LLC (TRC) | $3562 | 9897 | 0.03% | 股份 |
| OSAIC HOLDINGS, INC. | $3105 | 8625 | 0.02% | 股份 |
| Financial Perspectives, Inc | $2429 | 6750 | 0.02% | 股份 |
| GROUP ONE TRADING LLC | $673 | 1871 | 0.01% | 股份 |
| JPMORGAN CHASE & CO | $650 | 2108 | 0.00% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $284 | 790 | 0.00% | 股份 |
| SIMPLEX TRADING, LLC | $91 | 255 | 0.00% | 股份 |
| SBI Securities Co., Ltd. | $36 | 100 | 0.00% | 股份 |
激进投资者及 5%+ 股东 4 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. ×13 申报 | 2026年7月2日 | 4.10% | 修订 | · | SEC |
| MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, UBS Oncology Impact Fund L.P., MPM BioVentures 2014 GP LLC, MPM BioVentures 2014 LLC, Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, ANSBERT GADICKE, LUKE EVNIN, Todd Foley, MPM ASSET MANAGEMENT LLC, MPM ONCOLOGY INNOVATIONS FUND LP, MPM Oncology Innovations Fund GP LLC ×8 申报 | 2026年5月12日 | 3.80% | 修订 | · | SEC |
| Taiho Ventures LLC | 2021年5月13日 | · | 初始申报 | 董事会活动 | SEC |
| Arkin Bio Ventures 2 L.P., Arkin Bio Venture GPGP Ltd., Moshe Arkin, Alon Lazarus | 2021年5月10日 | · | 初始申报 | 董事会活动 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 20 位内幕人士 · 6 位高管 · 10 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Daniel J Hicklin | President and Chief Executive Officer | 2025年1月2日 A | · | 0 | 0 | $0 |
| Timothy W. Trost | Chief Financial Officer | 2025年1月2日 A | · | 0 | 0 | $0 |
| Chulani Karunatilake | Chief Technology Officer | 2025年1月2日 A | · | 0 | 0 | $0 |
| Ellen Lubman | Chief Business Officer | 2025年1月2日 A | · | 0 | 0 | $0 |
| Randi Isaacs | Chief Medical Officer | 2025年1月2日 A | · | 0 | 0 | $0 |
| Cynthia Seidel-Dugan | Chief Scientific Officer | 2024年1月2日 A | 164888 | 0 | 0 | $0 |
| Luke Evnin | 董事 | 2026年7月7日 S | 0 | 0 | 87 | $-3255563 |
| Michael B. Atkins | 董事 | 2025年6月12日 A | · | 0 | 0 | $0 |
| Anil K. Singhal | 董事 | 2025年6月12日 A | · | 0 | 0 | $0 |
| Meeta Chatterjee | 董事 | 2025年6月12日 A | · | 0 | 0 | $0 |
| Alon Lazarus | 董事 | 2025年6月12日 A | 2046634 | 0 | 0 | $0 |
| Briggs Morrison | 董事 | 2025年6月12日 A | · | 0 | 0 | $0 |
| Michael A. Sherman | 董事 | 2025年6月12日 A | · | 0 | 0 | $0 |
| Derek Dirocco | 董事 | 2024年5月24日 A | · | 0 | 0 | $0 |
| Sakae Asanuma | 董事 | 2021年5月4日 C | 2068909 | 0 | 0 | $0 |
| Taiho Ventures LLC | 10% 所有者 | 2021年5月4日 C | 2068909 | 0 | 0 | $0 |
| UPMC | 10% 所有者 | 2021年5月4日 C | 1097756 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | 10% 所有者 | 2021年5月4日 C | 625995 | 0 | 0 | $0 |
| Steven H. Bloom | · | 2025年5月1日 A | · | 0 | 0 | $0 |
| Reid Leonard | · | 2023年1月3日 A | 14102 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 2 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
HOWL 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 8 位分析师
买入
中位数目标
$7.00
+654.2%
2 25.0%
强烈买入
4 50.0%
买入
2 25.0%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
3 位分析师 · 2026-09-29平均目标 $7.00 +654.2%
← 低于所有目标
当前价格 $0.93
最低$4.00
平均值$7.00
最高$10.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 七月 31, 2026 申报